Flexicath, Inc., a medical device company that develops, manufactures and markets sterile catheter insertion systems, has received US FDA clearance for the Pressure Injectable M/29 Midterm Catheter Series, the latest addition to the M/29 family of midline catheters.

The M/29 Midterm is the world's first IV catheter solution to provide a "built in" 360-degree Maximum Barrier against airborne and touch-borne contamination during the insertion process and offers a simple to place intermediate dwell alternative for patients needing IV therapy for less than 30 days. The M/29 product suite now includes pressure injection rating up to 5 ml/sec, 3 FR catheters in 10 CM and 20CM lengths, and OTN Safety Introducers in 5CM and 7CM lengths. These new product capabilities extend the application of the M/29 in the clinical setting and include ultrasound assisted placement and contrast agent administration – providing additional tools for the vascular access specialist, improving patient satisfaction, and enabling better care.

PLSG invests in and supports the growth of biosciences companies in western Pennsylvania. PLSG has a track record of excellence when it comes to attracting and growing life sciences companies in the region.